Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Clinical-trials-phase-ii symbols : AZN save search
ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
Published: 2023-10-23 (Crawled : 20:00) - biospace.com/
AZN | $68.27 -0.67% -0.67% 3.8M
|
Health Technology
|
| O: -1.57%
H: 1.06%
C: 0.36%
enhertu her2 tumors trial phase 2
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
Published: 2023-07-27 (Crawled : 12:00) - biospace.com/
AZN | $68.27 -0.67% -0.67% 3.8M
|
Health Technology
|
| O: 0.42%
H: 0.55%
C: -0.86%
enhertu tumors trial
ENHERTU® Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
Published: 2023-07-27 (Crawled : 10:00) - biospace.com/
AZN | $68.27 -0.67% -0.67% 3.8M
|
Health Technology
|
| O: 0.42%
H: 0.55%
C: -0.86%
enhertu her2 tumors trial
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
Published: 2023-05-30 (Crawled : 13:00) - biospace.com/
AZNCF | $135.94 -4.19% 770
|
Health Technology
|
| O: -0.34%
H: 0.21%
C: -2.03%
GNPX | $2.29 -2.55% -2.62% 20K
|
Health Technology
|
| O: 1.12%
H: 2.16%
C: -10.76%
AZN | $68.27 -0.67% -0.67% 3.8M
|
Health Technology
|
| O: 0.44%
H: 0.03%
C: -1.94%
reqorsa lung approval review cancer cell expansion trial
Compugen Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed with TIGIT Bispecific Derived from COM902
Published: 2021-10-04 (Crawled : 14:00) - biospace.com/
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: 0.5%
H: 4.17%
C: 0.83%
AZN | $68.27 -0.67% -0.67% 3.8M
|
Health Technology
|
| O: 1.28%
H: 0.83%
C: 0.82%
milestone
Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021
Published: 2021-06-11 (Crawled : 11:00) - biospace.com/
FBIO | $1.79 -1.65% -1.68% 190K
|
Health Technology
|
| O: 3.49%
H: 0.9%
C: 0.9%
AZN | $68.27 -0.67% -0.67% 3.8M
|
Health Technology
|
| O: 0.49%
H: 0.03%
C: -0.61%
phase 2 europe als
Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021
Published: 2021-05-12 (Crawled : 22:00) - biospace.com/
FBIO | $1.79 -1.65% -1.68% 190K
|
Health Technology
|
| O: -0.79%
H: 2.93%
C: -1.87%
AZN | $68.27 -0.67% -0.67% 3.8M
|
Health Technology
|
| O: 1.15%
H: 0.55%
C: -0.4%
presentation europe
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.